Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel G Haller

Showing results (51-60 of 112) with videos related to

Pageof 12
Sort By:
Cancer|July 25, 2003
Influence of body mass index on outcomes and treatment-related toxicity in patients with colon carcinomaJeffrey A Meyerhardt, Paul J Catalano, Daniel G Haller, et al.
Cancer|April 4, 2003
Dose escalation study of tezacitabine in combination with cisplatin in patients with advanced cancerKeith T Flaherty, James P Stevenson, Maryann Gallagher, et al.
Cancer|July 19, 2006
Consensus report of the international society of gastrointestinal oncology on therapeutic progress in advanced pancreatic cancerHoward S Hochster, Daniel G Haller, Aimery de Gramont, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 30, 2005
Colon cancer survival is associated with decreasing ratio of metastatic to examined lymph nodesAdam C Berger, Elin R Sigurdson, Thomas LeVoyer, et al.
Annals of Surgical Oncology|April 8, 2003
Accuracy of determining nodal negativity in colorectal cancer on the basis of the number of nodes retrieved on resectionNatalie E Joseph, Elin R Sigurdson, Alexandra L Hanlon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 9, 2011
Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancerDaniel G Haller, Josep Tabernero, Jean Maroun, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 2008
Oxaliplatin plus irinotecan compared with irinotecan alone as second-line treatment after single-agent fluoropyrimidine therapy for metastatic colorectal carcinomaDaniel G Haller, Mace L Rothenberg, Alfred O Wong, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 30, 2003
Safety and toxicity analysis of oxaliplatin combined with fluorouracil or as a single agent in patients with previously treated advanced colorectal cancerRamesh K Ramanathan, Jeffery W Clark, Nancy E Kemeny, et al.
Clinical Colorectal Cancer|January 27, 2010
Current Opinion on Optimal Treatment Choices in First-line Therapy for Advanced or Metastatic Colorectal Cancer: Report From the Adelaide Colorectal Tumour Group Meeting; Stockholm, Sweden; September 2008Timothy J Price, Niall C Tebbutt, Christos S Karapetis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 2, 2015
Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer: Final Results of the NO16968 Randomized Controlled Phase III TrialHans-Joachim Schmoll, Josep Tabernero, Jean Maroun, et al.
Pageof 12

Showing results (51-60 of 112) with videos related to

Sort By:
Pageof 12
Cancer|July 25, 2003
Influence of body mass index on outcomes and treatment-related toxicity in patients with colon carcinomaJeffrey A Meyerhardt, Paul J Catalano, Daniel G Haller, et al.
Cancer|April 4, 2003
Dose escalation study of tezacitabine in combination with cisplatin in patients with advanced cancerKeith T Flaherty, James P Stevenson, Maryann Gallagher, et al.
Cancer|July 19, 2006
Consensus report of the international society of gastrointestinal oncology on therapeutic progress in advanced pancreatic cancerHoward S Hochster, Daniel G Haller, Aimery de Gramont, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 30, 2005
Colon cancer survival is associated with decreasing ratio of metastatic to examined lymph nodesAdam C Berger, Elin R Sigurdson, Thomas LeVoyer, et al.
Annals of Surgical Oncology|April 8, 2003
Accuracy of determining nodal negativity in colorectal cancer on the basis of the number of nodes retrieved on resectionNatalie E Joseph, Elin R Sigurdson, Alexandra L Hanlon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 9, 2011
Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancerDaniel G Haller, Josep Tabernero, Jean Maroun, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 2008
Oxaliplatin plus irinotecan compared with irinotecan alone as second-line treatment after single-agent fluoropyrimidine therapy for metastatic colorectal carcinomaDaniel G Haller, Mace L Rothenberg, Alfred O Wong, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 30, 2003
Safety and toxicity analysis of oxaliplatin combined with fluorouracil or as a single agent in patients with previously treated advanced colorectal cancerRamesh K Ramanathan, Jeffery W Clark, Nancy E Kemeny, et al.
Clinical Colorectal Cancer|January 27, 2010
Current Opinion on Optimal Treatment Choices in First-line Therapy for Advanced or Metastatic Colorectal Cancer: Report From the Adelaide Colorectal Tumour Group Meeting; Stockholm, Sweden; September 2008Timothy J Price, Niall C Tebbutt, Christos S Karapetis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 2, 2015
Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer: Final Results of the NO16968 Randomized Controlled Phase III TrialHans-Joachim Schmoll, Josep Tabernero, Jean Maroun, et al.
Pageof 12